All News
New Insights into Uveitis in Spondyloarthritis
Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis.
Read Article
ACR21 Best Abstracts We Saw - Day 3 (Monday)
The third day of ACR 2021 took a big leap in online content. Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.
Read Article
Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA across multiple domains. Listen to my interview with Prof. Laura Coates on this and other emerging treatments in PsA here https://t.co/PSbJ0HA5a6
@RheumNow #ACR21 Abstr#1335 https://t.co/WzBOYGOxAA
Dr. Antoni Chan synovialjoints ( View Tweet)
Will a FDA black box warning change your JAKi practice?
In May 2019, the EMA put out a warning about VTE with tofacitinib.
In this French cohort, did it change the kind of pts they initiated on JAKi?
no, not it did not😊
A window into the US future?
#ACR21 ABST1245 @RheumNow https://t.co/QI95E1gepg
David Liew drdavidliew ( View Tweet)
Are there people looking at steroid-sparing therapy as irAE treatment or prevention?
@CCalabreseDO: are there ever
#ACR21 irAE Study Group @RheumNow
(also @NAbdelwahabMD @ReidMDMPH on stage) https://t.co/CLmNaLB68O
David Liew drdavidliew ( View Tweet)
#ACR21 Abs#1536
#Vaccine uptake in people with #RheumaticDisease
👉🏼High uptake of vaccines in ~240 pts @BrighamWomens
👉🏼84% pts wanted the #COVID19 vaccine
👉🏼Physician recommendation was key determinant of uptake
@RheumNow
https://t.co/us0i5CW5Mi https://t.co/aLZmOPWFR3
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 #Abstr1492 Could gut microbiome contribute to Anti-Ro+/autoimmunity in #lupus? Analyses of 125 stool samples from mother of children with neonatal lupus and/or heart block revealed its potential role in genetic-environment interaction @RheumNow https://t.co/FnJtZJSCRj https://t.co/ttRdP9NIrG
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis
👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA
👉🏼No new safety risks with long-term use
👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX
Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Abs#1677. Effects of bDMARD on Lipids:
⬆️ HDL from 62 -> 66 in 1yr (p=0.013)
❌ No signif change in LDL or LDL-C/HDL-C ratios
@Rheumnow
https://t.co/uMsXKwwqvW https://t.co/fhCbDoa3px
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Ab#1681: ATI-450- MK2 Inhibitor
⭐️Downstream MK2 mediated inflamm drive of p38.
⭐️Hope this would avoid tachyphylaxis in p38 inhibitor meds
▶️Phase2a study in 19 pts: Well-tolerated (SEs: UTI, ventricular extrasystole), good 12 week data
@Rheumnow https://t.co/6lo7zPJUpx
Links:
Eric Dein ericdeinmd ( View Tweet)
Watch my video summary of abstracts #0380 and #0381 presented at the #ACR21 on #SickLeave and #WorkDisability in #axSpA by @ElenaNikiUK and colleagues.
@RheumNow https://t.co/HWEyPoPJi0
Mrinalini Dey DrMiniDey ( View Tweet)
SELECT-EARLY results for #upadacitinib in #RA
👉🏼UPA better than MTX for clinical response and remission
👉🏼⬆️rates of HZ, neutropenia, CPK elevations
👉🏼No new safety risks identified
Abs#1692 #ACR21 @RheumNow
https://t.co/wJy7MK4pyF https://t.co/YNpE1Axiw0
Mrinalini Dey DrMiniDey ( View Tweet)
For Dr @LianneGensler managing axSpA requires a sundae🍨approach! How cool is that?!😎
This means that we need to take a holistic approach on the management of axSpA - both non/pharmacologic & there's no one magic pill to treat the disease.
@RheumNow #ACR21 #RheumTwitter https://t.co/o0OjcEn16b
sheila RHEUMarampa ( View Tweet)
Sick Leave and Work Disability in Patients with AxSpA: Dr. Mrinalini Dey ( @DrMiniDey) discusses abstracts #0380 and #0381 presented at the #ACR21 annual meeting.
https://t.co/Wm4qpxerYJ https://t.co/6CwPrZjqJT
Links:
Dr. John Cush RheumNow ( View Tweet)
The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis
Dr. Richard Conway ( @RichardPAConway) reviews an abstract presented at #ACR21.
https://t.co/PkJmpODz8v https://t.co/zuJjofka3B
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of #ACR21 meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
great Thieves market
another dx to consider for ? inflammatory arthritis
swelling/stiffness post cold exposure
Microgeodic Disease-digital swelling/pain likely from bone infarction 2/2 to cold induced vasospasm
characteristic x ray/MRI findings on poster
#ACR21 #meded https://t.co/eq0aOlcB7I
Adam J Brown AdamJBrownMD ( View Tweet)
#ACR21 #IgG4 Q&A [Drs Stone/Perugino]
📌܄Igg4 in the blood/tissue is NOT diagnostic bec it can also be seen in others (malignancy..etc)
📌its more the presentation/ organ involvement see acr/eular guide: https://t.co/xBvu4r0TM3 https://t.co/WkiF6KyxGq
LiSa ◡̈︎ rheumarhyme ( View Tweet)
Upadacitinib 56-wk efficacy/safety (mod to severe PsA)
🔹Comparable or ⬆️efficacy vs adalimumab
🔹Efficacy maintained, and 15mg vs 30mg doses similar at 56wks
🔹No new safety findings @ 56wks
🔹🚫inc risk VTE, MACE, cancer vs ada
https://t.co/NlKvBrwDxB
#ACR21 Abst#1345 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Echos in PsA, RA:
🔹Diastolic dysfxn: 52% of PsA and RA (!), controls 5%
🔹Mitral regurge PsA 84%, Ra 53%, controls 10%
🔹Mild pulmonary valve regurge higher in PsA
(Diastolic dysfxn has been seen in prior RA studies)
https://t.co/QCKR5itfYj
#ACR21 Abst1308 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)